Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 6,660Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1Aarti Pharmalabs Limited

02 1Wavelength Enterprises LTD

03 1Dr. Reddy's Laboratories Limited

04 1Assia Chemical Industries Ltd. - Teva Tech Site

05 1Catalent Micron Technologies, Inc.

06 1Hetero Labs Limited

07 1Lonza Guangzhou Pharmaceutical Ltd.

08 4MSN Laboratories Private Limited

09 1Natco Pharma Limited

10 1SHILPA PHARMA LIFESCIENCES LIMITED

11 2ScinoPharm Taiwan Ltd.

filter clear-filterReset all filters

filter clear-filterReset all filters

PharmaCompass

01

arrow
BioAsia
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

IBRUTINIB

NDC Package Code : 15308-2402

Start Marketing Date : 2024-01-31

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (200kg/200kg)

Marketing Category : BULK INGREDIENT

Aarti Industries Company Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSeqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

IBRUTINIB

NDC Package Code : 58175-0602

Start Marketing Date : 2014-12-30

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

Seqens Company Banner

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

IBRUTINIB

NDC Package Code : 71796-053

Start Marketing Date : 2022-11-01

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

Dr Reddy Company Banner

04

PharmScience R&D
Not Confirmed
arrow
arrow
PharmScience R&D
Not Confirmed

IBRUTINIB

NDC Package Code : 63415-0531

Start Marketing Date : 2022-11-29

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (100kg/100kg)

Marketing Category : BULK INGREDIENT

blank

05

PharmScience R&D
Not Confirmed
arrow

06

PharmScience R&D
Not Confirmed
arrow

07

PharmScience R&D
Not Confirmed
arrow

08

PharmScience R&D
Not Confirmed
arrow

09

PharmScience R&D
Not Confirmed
arrow

10

PharmScience R&D
Not Confirmed
arrow
arrow
PharmScience R&D
Not Confirmed

IBRUTINIB

NDC Package Code : 63850-8089

Start Marketing Date : 2020-01-04

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

Looking for 936563-96-1 / Ibrutinib API manufacturers, exporters & distributors?

Ibrutinib manufacturers, exporters & distributors 1

100

PharmaCompass offers a list of Ibrutinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ibrutinib manufacturer or Ibrutinib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ibrutinib manufacturer or Ibrutinib supplier.

PharmaCompass also assists you with knowing the Ibrutinib API Price utilized in the formulation of products. Ibrutinib API Price is not always fixed or binding as the Ibrutinib Price is obtained through a variety of data sources. The Ibrutinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Ibrutinib

Synonyms

936563-96-1, Pci-32765, Imbruvica, Pci 32765, Ibrutinib (pci-32765), Pci-32765 (ibrutinib)

Cas Number

936563-96-1

Unique Ingredient Identifier (UNII)

1X70OSD4VX

About Ibrutinib

Ibrutinib is an orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B cell receptor signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. The expression of BTK in tumor cells is also associated with increased proliferation and survival.

Ibrutinib Manufacturers

A Ibrutinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ibrutinib, including repackagers and relabelers. The FDA regulates Ibrutinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ibrutinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Ibrutinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Ibrutinib Suppliers

A Ibrutinib supplier is an individual or a company that provides Ibrutinib active pharmaceutical ingredient (API) or Ibrutinib finished formulations upon request. The Ibrutinib suppliers may include Ibrutinib API manufacturers, exporters, distributors and traders.

click here to find a list of Ibrutinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Ibrutinib NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ibrutinib as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Ibrutinib API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Ibrutinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Ibrutinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ibrutinib NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Ibrutinib suppliers with NDC on PharmaCompass.

Ibrutinib Manufacturers | Traders | Suppliers

Ibrutinib Manufacturers, Traders, Suppliers 1
Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.